Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine

Steven R. Goodman, Betty Sue Pace, Kirk C. Hansen, Angelo D’alessandro, Yang Xia, Ovidiu Daescu, Stephen J. Glatt

Research output: Contribution to journalArticle

9 Scopus citations


In this review, we provide a description of those candidate biomarkers which have been demonstrated by multiple-omics approaches to vary in correlation with specific clinical manifestations of sickle cell severity. We believe that future clinical analyses of severity phenotype will require a multiomic analysis, or an omics stack approach, which includes integrated interactomics. It will also require the analysis of big data sets. These candidate biomarkers, whether they are individual or panels of functionally linked markers, will require future validation in large prospective and retrospective clinical studies. Once validated, the hope is that informative biomarkers will be used for the identification of individuals most likely to experience severe complications, and thereby be applied for the design of patient-specific therapeutic approaches and response to treatment. This would be the beginning of precision medicine for sickle cell disease.

Original languageEnglish (US)
Pages (from-to)772-781
Number of pages10
JournalExperimental Biology and Medicine
Issue number7
Publication statusPublished - Jan 1 2016



  • Genomics
  • interactomics
  • metabolomics
  • precision medicine
  • proteomics
  • sickle cell disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this